EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the anti-EGFR agent erlotinib within the phase 3 randomised AIO-PK0104 study.

Bibliographic Details

Main Authors:	Böck, Stefan (Author) , Jung, A. (Author) , Laubender, R. P. (Author) , Neumann, J. (Author) , Egg, R. (Author) , Goritschan, C. (Author) , Vehling-Kaiser, U. (Author) , Winkelmann, C. (Author) , Fischer von Weikersthal, L. (Author) , Clemens, M. R. (Author) , Gauler, T. C. (Author) , Märten, Angela (Author) , Klein, S. (Author) , Kojouharoff, G. (Author) , Barner, M. (Author) , Geissler, M. (Author) , Greten, T. F. (Author) , Mansmann, U. (Author) , Kirchner, T. (Author) , Heinemann, V. (Author)
Format:	Article (Journal)
Language:	English
Published:	2013
In:	British journal of cancer Year: 2012, Volume: 108, Issue: 2, Pages: 469-476
ISSN:	1532-1827
DOI:	10.1038/bjc.2012.495
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bjc.2012.495 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bjc2012495
Author Notes:	S. Boeck, A. Jung, R.P. Laubender, J. Neumann, R. Egg, C. Goritschan, U. Vehling-Kaiser, C. Winkelmann, L. Fischer von Weikersthal, M.R. Clemens, T.C. Gauler, A. Märten, S. Klein, G. Kojouharoff, M. Barner, M. Geissler, T.F. Greten, U. Mansmann, T. Kirchner and V. Heinemann